We are live on ! Find out more
NWBOW

Northwest Biotherapeutics, Inc.
NWBOW

Delisted

NWBOW was delisted on the 16th of December, 2016.

Back to rankings

1 hedge funds and large institutions have $3K invested in Northwest Biotherapeutics, Inc. in 2015 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 0 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 1 → 1 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

99% less capital invested

Capital invested by funds: $501K → $3K (-$498K)

Holders
1
Holders Change
–
Holders Change %
0%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$5.57K

Top Sellers

Rank Fund Capital Flow
1
Allianz Asset Management
Allianz Asset Management
Germany
-$501K
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
1
UBS Group
Switzerland
$3K +$5.57K +963 New
Allianz Asset Management
2
Allianz Asset Management
Germany
– -$501K -81,620 Closed

NWBOW Hedge Fund Activity: Q3 2015 in Review

1 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. (NWBOW) for Q3 2015, worth a combined $3K — down 99% from $501K a quarter earlier.

Fund positioning in NWBOW was balanced in Q3 2015: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.

The largest buyer was UBS Group, opening a new position worth an estimated $5.57K. The largest seller was Allianz Asset Management, exiting entirely with an estimated $501K sold.

  • 1 institutional investor held Northwest Biotherapeutics, Inc. (NWBOW) as of Q3 2015, unchanged from Q2 2015.
  • Funds reported $3K of Northwest Biotherapeutics, Inc. stock for Q3 2015, down 99% quarter-over-quarter.
  • 1 fund opened new Northwest Biotherapeutics, Inc. positions in Q3 2015 and 1 closed out, a net change of 0 holders.
  • The largest Northwest Biotherapeutics, Inc. buyer in Q3 2015 was UBS Group, an estimated $5.57K added.
  • The largest Northwest Biotherapeutics, Inc. seller in Q3 2015 was Allianz Asset Management, an estimated $501K sold.

Based on aggregated 13F filings for Q3 2015.